Pharmacist-managed titration of urate-lowering therapy to streamline gout management

被引:8
作者
Huang, Irvin J. [1 ]
Liew, Jean W. [2 ]
Morcos, Meredith B. [3 ]
Zuo, Silu [4 ]
Crawfords, Carol [5 ]
Bays, Alison M. [2 ]
机构
[1] Univ Washington, Dept Med, Boise, ID USA
[2] Univ Washington, Dept Med, Div Rheumatol, Seattle, WA 98195 USA
[3] Virginia Mason Med Ctr, Rheumatol, Seattle, WA 98101 USA
[4] Univ Washington, Pharm, Seattle, WA 98195 USA
[5] Harborview Med Ctr, Pharm, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
Crystal arthropathies; Hyperuricemia; Gout; Patient compliance; US GENERAL-POPULATION; CARE; ADHERENCE; HYPERURICEMIA; PREVALENCE; GUIDELINES; HEALTH; TARGET; TREAT;
D O I
10.1007/s00296-019-04333-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The treat-to-target approach for serum uric acid is the recommended model in gout management according to the 2012 American College of Rheumatology (ACR) guidelines. Adherence to urate-lowering therapy (ULT) can be difficult for patients due to barriers, which include medication burden, financial hardship, and lack of medical literacy. Our aim was to create a pharmacist-managed referral for the titration of ULT to target serum uric acid (sUA) levels in a complex patient population. We utilized a clinical database to query patients seen at a rheumatology clinic over a 12-month period with an ICD-10 diagnosis for gout. The referral criteria were indications for ULT per the 2012 ACR guidelines. Rheumatology providers, consisting of attendings, fellows, and a physician assistant, were asked to refer the identified patients to the pharmacist-managed titration program. The intervention group consisted of 19 referred patients and the control group consisted of 28 non-referred patients. The baseline sUA (median (IQR)) at the time of referral was 8.8 (2) mg/dL for the intervention group and 7.6 (2.8) mg/dL for the control group (p = 0.2). At the end of the study period, the sUA was 6.1 (1.4) mg/dL for the intervention group and 6.8 (3.2) mg/dL for the control group (p = 0.08). At the end of the study period, 6 of 19 (32%) intervention group and 7 of 28 (25%) control group were at goal (p = 0.3). A newly instituted pharmacist-managed titration program was able to achieve lower average sUA levels in referred patients compared to demographically similar individuals who received standard gout management.
引用
收藏
页码:1637 / 1641
页数:5
相关论文
共 50 条
  • [21] Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout
    Graham, Garry G.
    Stocker, Sophie L.
    Kannangara, Diluk R. W.
    Day, Richard O.
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (08)
  • [22] Rebranding Gout: Could a Name Change for Gout Improve Adherence to Urate-Lowering Therapy?
    Coleshill, Matthew J.
    Aung, Eindra
    Carland, Jane E.
    Faasse, Kate
    Stocker, Sophie
    Day, Richard O.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (01) : 138 - 141
  • [23] Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review
    Sinnappah, Klarissa A.
    Stocker, Sophie L.
    Chan, Jian Sheng
    Hughes, Dyfrig A.
    Wright, Daniel F. B.
    INTERNATIONAL JOURNAL OF PHARMACY PRACTICE, 2022, 30 (03) : 215 - 225
  • [24] Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout
    Yen, Fu-Shun
    Hsu, Chih-Cheng
    Li, Hsin-Lun
    Wei, James Cheng-Chung
    Hwu, Chii-Min
    PLOS ONE, 2020, 15 (06):
  • [25] Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout
    Yen, Fu-Shun
    Hsu, Chih-Cheng
    Li, Hsin-Lun
    Wei, James Cheng-Chung
    Hwu, Chii-Min
    FRONTIERS IN MEDICINE, 2020, 7
  • [26] Gout, Urate-Lowering Therapy, and Uric Acid Levels Among Adults in the United States
    Juraschek, Stephen P.
    Kovell, Lara C.
    Miller, Edgar R.
    Gelber, Allan C.
    ARTHRITIS CARE & RESEARCH, 2015, 67 (04) : 588 - 592
  • [27] Lowering Serum Urate With Urate-Lowering Therapy to Target and Incident Fracture Among People With Gout
    Wei, Jie
    Choi, Hyon K.
    Dalbeth, Nicola
    Lane, Nancy E.
    Wu, Jing
    Lyu, Houchen
    Zeng, Chao
    Lei, Guanghua
    Zhang, Yuqing
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 (08) : 1456 - 1465
  • [28] Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes
    Guma, Monica
    Dadpey, Benyamin
    Coras, Roxana
    Mikuls, Ted R.
    Hamilton, Bartlett
    Quehenberger, Oswald
    Thorisdottir, Hilda
    Bittleman, David
    Lauro, Kimberly
    Reilly, Shannon M.
    Liu-Bryan, Ru
    Terkeltaub, Robert
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [29] Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study
    Ebstein, Esther
    Forien, Marine
    Norkuviene, Eleonora
    Richette, Pascal
    Mouterde, Gael
    Daien, Claire
    Ea, Hang-Korng
    Briere, Claire
    Liote, Frederic
    Petraitis, Mykolas
    Bardin, Thomas
    Ora, Jeremy
    Dieude, Philippe
    Ottaviani, Sebastien
    RHEUMATOLOGY, 2019, 58 (03) : 410 - 417
  • [30] Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis
    Sharma, Gaurav
    Dubey, Abhishek
    Nolkha, Nilesh
    Singh, Jasvinder A.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13